We noticed JavaScript is turned off in your browser settings. For a better viewing experience, enable JavaScript. If you're unsure of how to do this, click here to download a new browser.

FOR PREVIEW ONLY (Print)

Beth Y. Karlan, MD

Director, Women's Cancer Program in the Samuel Oschin Comprehensive Cancer Institute

Director, Division of Gynecologic Oncology

Director, Gilda Radner Hereditary Cancer Program

Board of Governors Chair in Gynecologic Oncology

Professor, Obstetrics and Gynecology

Samuel Oschin Comprehensive Cancer Center
8700 Beverly Blvd.
North Tower Lower Level
Los Angeles, CA 90048

Phone:

310-423-3302

Fax:

310-423-9753

Parking Instructions:

Parking is available on the corner of Beverly Blvd. and San Vicente Blvd.

Beth Y. Karlan, MD

Director, Women's Cancer Program in the Samuel Oschin Comprehensive Cancer Institute

Director, Division of Gynecologic Oncology

Director, Gilda Radner Hereditary Cancer Program

Board of Governors Chair in Gynecologic Oncology

Professor, Obstetrics and Gynecology

  • OB/GYN-Oncology

BRCA (Mutation, Positive, Carrier)

Cervical Cancers

Fallopian Tube Cancers

Gestational Trophoblast Disease

Ovarian Cancers

Pelvic Mass

Postmenopausal Bleeding

Uterine Cancers

Vaginal Cancers

Vulvar Cancers

The research studies of Beth Karlan, MD, focuses on ovarian cancer specific biomarkers for early detection, prognostication and targeted/individualized therapy, and inherited cancer susceptibility.

  • Medical School: Harvard Medical School, 1982
  • Internship: Yale-New Haven Hospital, 1983
  • Residency: Yale-New Haven Hospital, 1986
  • Fellowship: UCLA Medical Center, 1989
  • Editor-in-Chief: Gynecologic Oncology, Current
  • Distinguished Service Award, Society of Gynecologic Oncology — recognizing achievements as Editor-in-Chief of Gynecologic Oncology Journal and Gynecologic Oncology Reports, 2015
  • Claudia Cohen Research Foundation Prize for Outstanding Cancer Researcher, 2015
  • Member, National Cancer Advisory Board, 2012
  • Clinical Research Professorship: American Cancer Society, 2011
  • Prize for Excellence in Ovarian Cancer Research, Gynecologic Cancer Foundation, 2008
  • Board of Governors Chair in Gynecologic Oncology, 1995

Show moreShow less

  • Karlan BY, Oza AM, Richardson GE, Provencher DM, Hansen VL, Buck M, Chambers SK, Ghatage P, Pippitt CH Jr, Brown JV 3rd, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2011;30(4):362-371.
  • Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian cancer mortality. Nature. 2011;474(7353):609-615.
  • Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecol Oncol. 2014;132(2):334-342.
  • Karlan BY, Thorpe J, Watabayashi K, Drescher CW, Palomares M, Daly MB, Paley P, Hillard P, Andersen MR, Anderson G, et al. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1383-1393.

Show moreShow less

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or